Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7,010 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia.
Lee JH, Kim H, Joo YD, Lee WS, Bae SH, Zang DY, Kwon J, Kim MK, Lee J, Lee GW, Lee JH, Choi Y, Kim DY, Hur EH, Lim SN, Lee SM, Ryoo HM, Kim HJ, Hyun MS, Lee KH; Cooperative Study Group A for Hematology. Lee JH, et al. Among authors: kwon j. J Clin Oncol. 2017 Aug 20;35(24):2754-2763. doi: 10.1200/JCO.2017.72.8618. Epub 2017 Jun 20. J Clin Oncol. 2017. PMID: 28632487 Clinical Trial.
Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients.
Park JS, Lee SE, Jeong SH, Jang EJ, Choi MY, Kim HJ, Kim YK, Kim SH, Zang DY, Oh S, Koo DH, Kim H, Do YR, Kwak JY, Kim JA, Kim DY, Mun YC, Lee WS, Chang MH, Park J, Kwon JH, Kim DW. Park JS, et al. Among authors: kwon jh. Leuk Lymphoma. 2016 Feb;57(2):341-347. doi: 10.3109/10428194.2015.1049166. Epub 2015 Jun 12. Leuk Lymphoma. 2016. PMID: 25947037
Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study.
Lee SE, Choi SY, Song HY, Kim SH, Choi MY, Park JS, Kim HJ, Kim SH, Zang DY, Oh S, Kim H, Do YR, Kwak JY, Kim JA, Kim DY, Mun YC, Lee WS, Chang MH, Park J, Kwon JH, Kim DW. Lee SE, et al. Among authors: kwon jh. Haematologica. 2016 Jun;101(6):717-23. doi: 10.3324/haematol.2015.139899. Epub 2016 Feb 17. Haematologica. 2016. PMID: 26888022 Free PMC article.
Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study.
Kwon J, Min CK, Kim K, Han JJ, Moon JH, Kang HJ, Eom HS, Kim MK, Kim HJ, Yoon DH, Lee JO, Lee WS, Lee JH, Lee JJ, Choi YS, Kim SH, Yoon SS. Kwon J, et al. Cancer Med. 2017 Jan;6(1):100-108. doi: 10.1002/cam4.970. Epub 2016 Dec 1. Cancer Med. 2017. PMID: 27905203 Free PMC article.
Real-world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis.
Yi JH, Kim SJ, Yoon DH, Suh C, Chang MH, Yang DH, Jo JC, Hyun SY, Eom HS, Lee JO, Kwon JH, Han SH, Lee SS, Kwak JY, Kim SH, Kim DS, Lee JH, Oh SY, Ryoo HM, Kim HJ, Kim WS. Yi JH, et al. Cancer Commun (Lond). 2021 Mar;41(3):275-278. doi: 10.1002/cac2.12150. Epub 2021 Feb 24. Cancer Commun (Lond). 2021. PMID: 33626235 Free PMC article. No abstract available.
7,010 results